To ask His Majesty's Government whether a recommendation by Rapid C-19 is stopping the provision of Evusheld in the NHS by Christmas.
22 November 2022
The decision not to procure Evusheld at this time for prevention through emergency routes is based on independent clinical advice by the multi-agency RAPID C-19 and a national expert policy working group. This is based on a range of evidence, including clinical trial data, in vitro analysis and emerging observational studies. The Chief Medical Officer for England is content that the correct process for providing clinical advice has been followed and it has now been referred to the National Institute for Health and Care Excellence (NICE) for further evaluation. NICE’s appraisal is expected to be completed by April 2023 and should it conclude the treatment is cost-effective, it would support deployment next year.